New study tracks Mylotarg's safety in korean AML patients
NCT ID NCT05189639
First seen Nov 19, 2025 · Last updated May 25, 2026 · Updated 18 times
Summary
This study watches adults in Korea who are already receiving Mylotarg for newly diagnosed acute myeloid leukemia (AML). Researchers will track side effects and how the disease responds. The goal is to learn more about the drug's safety and effects in real-world use. No new treatment is given—participants continue their regular care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul national university hospital
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.